Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity

Clinical Lung Cancer

Volumn 11, Issue 6, 2010, Pages 405-411

  Mahesh, Sameer ^a,b   Saxena, Ashish ^a   Qiu, Xuan ^a   Perez Soler, Roman ^a   Zou, Yiyu ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

Aerosol administration; Airway epithelium; Demethylation

Indexed keywords

AZACITIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUNG CANCER; LUNG TOXICITY; LUNG TRANSPLANTATION; MALE; MOUSE; NONHUMAN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED ICR; MICE, NUDE; TRACHEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649261580     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.052     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105:31-52.
3. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4:707-17.
4. Zöchbauer-Müller S, Minna JD, Gazdar A F. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002; 7:451-7.
5. Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21:5450-61.
6. Otterson GA, Kratzke RA, Coxon A, et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene 1994; 9:3375-8.
7. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1:686-92.
8. Georgiou E, Valeri R, Tzimagiorgis G, et al. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking. Eur J Cancer Prev 2007; 16:396-402.
9. Buckingham L, Penfield Faber L, Kim A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II non small cell lung cancer patients. Int J Cancer 2010; 126:1630-9.
10. Tang X, Wu W, Sun SY, et al. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res 2004; 2:685-91.
11. Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 2001; 264:185-92.
12. Kim DS, Kim MJ, Lee JY, et al. Aberrant methylation of E-cadherin and H-cadherin genes in non small cell lung cancer and its relation to clinicopathologic features. Cancer 2007; 110:2785-92.
13. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008; 99:375-82.
14. Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10:176-82.
15. Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol 2005; 32:443-51.
16. Marquez VE, Kelley JA, Agbaria R, et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 2005; 1058:246-54.
17. Mufti G, List A F, Gore SD, et al. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2003; 176-99.
18. Momparler RL, Bouffard DY, Momparler L F, et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-cancer Drugs 1997; 8:358-68.
19. Carmichael J, DeGraff WG, Gazdar A F, et al. Evaluation of a tetrazolium-based semi automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-42.
20. Wang Y, Yu Z, Wang T, et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007; 56:289-94.
21. Zou Y, Zong G, Ling YH, et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst 1998; 90:1130-7.
22. Zou Y, Ling YH, Van NT, et al. Antitumor activity of free and liposome-en-trapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994; 54:1479-84.
23. Zou Y, Zong G, Ling YH, et al. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 2000; 7:683-96.
24. Zou Y, Yamagishi M, Horikoshi I, et al. Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. Cancer Res 1993; 53:3046-51.
25. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA meth-ylation. Cell 1980; 20:85-93.
26. Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91:11797-801.
27. Digel W, Lübbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 2005; 55:1-11.